NASDAQ · ABUS
Arbutus Biopharma Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ABUS: Nov 12, 2026
Arbutus Biopharma Corporation Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.04.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · NASDAQ.com · BNK Invest- Fintel · Oct 22, 11:43 AM EDTArbutus Biopharma Corporation Announces FDA Lifts Clinical Hold on IND Application for AB-101On October 22, 2026, Arbutus Biopharma Corporation announced that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company’s oral PD-L1 inhibitor. The removal of the hold allows the Company to eng
- RTTNews · Oct 22, 10:12 AM EDTArbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B Program(RTTNews) – Arbutus Biopharma (ABUS) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its investigational new drug application for AB-101, an oral PD-L1 inhibitor being developed for chronic hepatitis B virus (HBV) infection.
- NASDAQ.com · Sep 25, 4:24 PM EDTAfter Hours Most Active for Sep 25, 2026 : FTXN, ABUS, FTXH, CMCSA, NVDA, CSCO, JPM, BMNR, EQT, CNP, PFE, CVSThe NASDAQ 100 After Hours Indicator is up 5.94 to 30,614.08. The total After hours volume is currently 139,531,265 shares traded.The following are the most active stocks for the after hours session: First Trust Nasdaq Oil & Gas ETF (FTXN) is -0.12 at $38.48, with 20,767,281
- NASDAQ.com · Sep 22, 4:24 PM EDTAfter Hours Most Active for Sep 22, 2026 : RIG, NIO, INTC, NVDA, QQQ, CSCO, CDE, ABUS, BMY, NU, AAPL, BACThe NASDAQ 100 After Hours Indicator is down -27.89 to 30,704.51. The total After hours volume is currently 183,103,979 shares traded.The following are the most active stocks for the after hours session: Transocean Ltd. (RIG) is -0.01 at $5.48, with 12,770,225 shares traded. RIG
- BNK Invest · Sep 22, 3:22 PM EDTNoteworthy Tuesday Option Activity: ALAB, ABUS, PORAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Astera Labs Inc (Symbol: ALAB), where a total of 33,360 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 88.
- NASDAQ.com · Sep 4, 4:29 PM EDTAfter Hours Most Active for Sep 4, 2026 : NIO, INTC, TEVA, AMZN, F, NVDA, XOM, KO, CNH, ABUS, META, SMCIThe NASDAQ 100 After Hours Indicator is down -45.18 to 29,498.97. The total After hours volume is currently 112,199,562 shares traded.The following are the most active stocks for the after hours session: NIO Inc. (NIO) is +0.0015 at $3.80, with 7,386,156 shares traded. NIO's cur
- RTTNews · Aug 24, 8:56 AM EDTArbutus Launches $230M Tender Offer For Shares At $5.00-$5.75 Per Share; Stock Up(RTTNews) – Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company, announced the commencement of a modified "Dutch Auction" tender offer to purchase for cancellation up to $230 million of its common shares.
- RTTNews · Aug 21, 10:28 AM EDTArbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback(RTTNews) – Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent s
- RTTNews · Aug 21, 9:00 AM EDTArbutus Biopharma Launches $230 Mln Share Buyback Via Dutch Auction; Shares Up In Pre-market(RTTNews) – Arbutus Biopharma Corp. (ABUS) Friday announced a plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders.
- RTTNews · Aug 12, 2:49 PM EDTArbutus Advances Imdusiran; FDA Aligns On Phase 2b Trial Design(RTTNews) – Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported second-quarter 2026 financial results and corporate updates, highlighting progress with imdusiran for chronic hepatitis B, a strong financial posi
- Zacks · Jul 31, 2:04 PM EDTMRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine SetbackModerna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
- RTTNews · Jul 16, 8:39 AM EDTArbutus, Genevant File International Lawsuits Against Pfizer, BioNTech(RTTNews) – Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences – a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to enforce patents protecting their LNP technology against Pfizer, BioNTech SE and certain of their affilia
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Arbutus Biopharma Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.